Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (511-520 of 759) with videos related to

Pageof 76
Sort By:
British Journal of Haematology|April 14, 2006
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial, Rafael Fonseca, Morie A Gertz, et al.
American Journal of Hematology|July 6, 2019
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S Al Saleh, M Hasib Sidiqi, Surbhi Sidana, et al.
American Journal of Hematology|October 16, 2019
Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patientsAbdullah S Al Saleh, M Hasib Sidiqi, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
Pageof 76

Showing results (511-520 of 759) with videos related to

Sort By:
Pageof 76
British Journal of Haematology|April 14, 2006
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial, Rafael Fonseca, Morie A Gertz, et al.
American Journal of Hematology|July 6, 2019
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S Al Saleh, M Hasib Sidiqi, Surbhi Sidana, et al.
American Journal of Hematology|October 16, 2019
Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patientsAbdullah S Al Saleh, M Hasib Sidiqi, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
Pageof 76